News

Science Daily4h
Reactivity to tumor antigens is important for TIL therapy
A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...
Reactivity to tumor antigens is important for tumor-infiltrating lymphocyte therapy, study shows
A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...
Enhanced CAR T cell therapy offers new strategy for lymphoma
A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...
El Mundo on MSN15h
A new version of CAR-T improves response in lymphomas that do not respond to available therapies
In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...
L'Usine Nouvelle3d
Dans les pipelines : Merck, Regeneron, Pfizer
D’après les résultats d’une étude de phase III, l’utilisation de Keytruda (pembrolizumab), avant et après la chirurgie, a ...